About ADCETRIS® (brentuximab vedotin) ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting ...

Adcetris was recently approved by the FDA in 2011, so it’s fairly new, but Kathleen, a local cancer survivor who relapsed three times, said the drug has been a miracle for her.

Adcetris is the first drug approved for the Hodgkin's lymphoma since 1977. The FDA sped approval up under an accelerated, six month system reserved for therapies that show promising results in ...

Adcetris is approved for use in children ages 2 years and older with high risk cHL that has not been treated before. For this use, the typical dosage is 1.8 mg/kg once every 3 weeks.

The combination of Adcetris, Revlimid and Rituxan significantly increased overall survival compared with Revlimid/Rituxan alone in patients with relapsed/refractory diffuse large B-cell lymphoma ...

ADCETRIS (brentuximab vedotin) was issued marketing authorization under the NOC/c policy based on results from a single-arm, phase II pivotal trial in HL patients with relapsed or refractory ...

The FDA approved Adcetris (brentuximab vedotin; Seattle Genetics) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).

NICE calculated that Adcetris will likely cost below £30,000 per Quality Adjusted Life Year, its upper threshold in normal situations, and is therefore a cost-effective use of NHS resources.

Adcetris is available as a 50mg/vial lyophilized powder for intravenous (IV) infusion in single-use vials. For more information call (855) 473-2436 or visit Adcetris.com.

Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, ...

ADCETRIS is contraindicated for patients with hypersensitivity to brentuximab vedotin and its excipients. In addition, combined use of ADCETRIS with bleomycin causes pulmonary toxicity.

Adcetris is prescribed with chemotherapy for stage 3 or stage 4 cHL that hasn’t been treated yet. The typical dose for this use is 1.2 mg/kg, up to a maximum of 120 mg per dose.